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Abstract
Background: Administering stereotactic radiotherapy to the surgical cavity and thus omitting postoperative whole
brain radiotherapy (WBRT) is a favored strategy in limited metastatic brain disease. Little is known about the impact
of regular magnetic resonance imaging follow-up (MRI FU) in such patient cohorts. The aim of this study is to
examine the impact of regular MRI FU and to report the oncological outcomes of patients with one to three
brain metastases (BMs) treated with stereotactic radiosurgery (SRS) or hypo-fractionated stereotactic radiotherapy
(HFSRT) to the surgical cavity.
Methods: We retrospectively analyzed patients who received SRS or HFSRT to the surgical cavity after resection
of one to two BMs. Additional, non-resected BMs were managed with SRS alone. Survival was estimated by the
Kaplan-Meier method. Prognostic factors were examined with the log-rank test and Cox proportional hazards model.
Regular MRI FU was defined as performing a brain MRI 3 months after radiotherapy (RT) and/or performing ≥1 brain
MRI per 180 days. Primary endpoint was local control (LC). Secondary endpoints were distant brain control (DBC),
overall survival (OS) and the correlation between regular MRI FU and overall survival (OS), symptom-free survival (SFS),
deferment of WBRT and WBRT-free survival (WFS).
Results: Overall, 75 patients were enrolled. One, 2 and 3 BMs were seen in 63 (84%), 11 (15%) and 1 (1%) patients,
respectively. Forty (53%) patients underwent MRI FU 3months after RT and 38 (51%) patients received ≥1 brain MRI
per 180 days. Median OS was 19.4 months (95% CI: 13.2–25.6 months). Actuarial LC, DBC and OS at 1 year were 72%
(95% CI: 60–83%), 60% (95% CI: 48–72%) and 66% (95% CI: 53–76%), respectively. A planning target volume > 15 cm3
(p = 0.01), Graded Prognostic Assessment (GPA) score (p = 0.001) and residual tumor after surgery (p = 0.008) were
prognostic for decreased OS in multivariate analysis. No significant correlation between MRI FU at 3 months and
OS (p = 0.462), SFS (p = 0.536), WFS (p = 0.407) or deferment of WBRT (p = 0.955) was seen. Likewise, performing
≥1 MRI per 180 days had no significant impact on OS (p = 0.954), SFS (p = 0.196), WFS (p = 0.308) or deferment of
WBRT (p = 0.268).
Conclusion: Our results regarding oncological outcomes consist with the current data from the literature. Surprisingly,
regular MRI FU did not result in increased OS, SFS, WFS or deferment of WBRT in our cohort consisting mainly of
patients with a single and resected BM. Therefore, the impact of regular MRI FU needs prospective evaluation.
Trial registration: Project ID: 2017–00033, retrospectively registered.
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Introduction
Brain metastases (BMs) are the most common tumors
in the central nervous system (CNS) in adults [1].
Population-based studies show incidence rates of brain
metastases ranging from 8.3 to 14.3 per 100,000 popu-
lation. Among cancer patients, the incidence ranges
from 8.5–9.6% [2], and 20 to 40% of patients with can-
cer develop brain metastases during the course of their
disease [3]. Since the past two decades the incidence of
BM is rising as a consequence of increased availability
of magnetic resonance imaging (MRI) [4] and longer
survival from primary cancers, due to new and more
effective systemic therapy options [2]. The most com-
mon primary tumors to metastasize to the brain are
lung cancer (50–60%), breast cancer (15–20%) and me-
lanoma (5–10%), while tumors of the gastrointestinal
tract and renal cell carcinomas (RCC) are less common
[1, 5]. Most patients present with oligometastatic brain
disease, which is defined as a limited number (usually 1
to 3) of intracranial metastases [6]. Surgery, radiosur-
gery, and whole-brain radiotherapy (WBRT) are the
main treatment options depending on individual dis-
ease characteristics [7]. Recently, two randomized trials
have been published [6, 8], addressing the fact that
stereotactic radiosurgery (SRS) alone may be a pre-
ferred strategy for a limited number of unresected and
resected brain metastases. No survival difference in the
SRS alone vs. the WBRT group, but less cognitive de-
terioration as well as a higher quality of life (QoL) at 3
months with SRS alone was shown in both trials. On
the other hand, time to intracranial failure was signifi-
cantly shorter for SRS alone compared with SRS plus
WBRT in both trials. The 6- and 12-month local and
distant tumor control rates were also significantly
higher in patients who received WBRT (p < 0.001).
Additionally, fewer patients underwent salvage therapy
after SRS plus WBRT than after SRS alone (7.8% vs
32.4%, respectively; difference, − 24.6%; 95% CI, − 35.7
to − 13.5%; p < 0.001). Lester et al. [9] showed that
patients presenting with symptomatic brain recurrences
would have worse clinical outcomes and create more
costs for a healthcare system in comparison to asymptom-
atic patients with recurrences detected with routine sur-
veillance imaging. Therefore, the importance of frequent
surveillance imaging emerges with those concerns [10].
The National Comprehensive Cancer Network (NCCN)
guidelines for limited numbers of BMs recommend
follow-up (FU) with MRI every 2–3months in the first
year and thereafter every 4 to 6months indefinitely [11].
However, there is little data about the actual impact of
regular FU with MRI.
The aim of this retrospective, single center study is to
report the potential benefit of regular MRI FU as well as
the oncological outcomes and toxicity rates in patients
with one to three BMs, who received surgery of at least
one BM and post-operative local radiation treatment
(SRS or hypo-fractionated stereotactic radiotherapy




Medical records of patients with resected BMs and up to
two unresected metastases were reviewed. Patients were
treated between 2010 and 2015 at the Bern University
Hospital with surgery of at least one BM followed by
post-operative local radiation treatment (SRS or HFSRT)
to the resection cavity and SRS to the remaining BMs.
Eligibility criteria included patients older than 18 years
with any non-CNS primary tumor histology and stage,
Eastern Cooperative Oncology Group (ECOG) perfor-
mance status 0–2, and the resected tissue had to be
confirmed as metastatic histologically, consistent with
a non-CNS primary site. Patients were excluded if they
had prior cranial radiotherapy (RT), fractionation was
> 10 and if there was no foreseen MRI FU or no avai-
lable FU data. Patient data included: age, gender, per-
formance status (ECOG score), graded prognostic
assessment (GPA) score, primary tumor histology,
number of BMs and location within the brain, if the
BMs were symptomatic at diagnosis (yes vs. no) and if
progressive or new neurological symptoms appeared
after RT (yes vs. no), pre-RT resection status (gross
total resection vs. subtotal resection), extracranial
tumor disease status (continuously evaluated during
the course of the disease), initial brain metastasis
velocity (iBMV, according to Soike et al. [12]), brain
metastasis velocity (BMV, according to Ferris et al.
[13]), use of any systemic treatment, use and modality
(surgery, radiosurgery and WBRT) of salvage treat-
ment, site and timing of salvage therapy, date of every
MRI FU and if MRI FU at 3 months and/or ≥ 1 MRI
per 180 days was performed (yes vs. no).
Stereotactic radiotherapy
According to institutional guidelines, the resection cav-
ities were treated using robotic (Cyberknife, Accuray,
Sunnyvale, USA) and Linac (Novalis, BrainLAB, Munich,
Germany) based SRS, if the volume of the resection
cavity was < 15 cm3 and HFSRT if the volume of the
resection cavity was > 15 cm3. It was at the physician’s
discretion to deviate from this standard procedure and
to adapt the fractionation scheme according to the cli-
nical situation in exceptional cases. The synchronous
unresected metastases were treated with SRS alone.
Patients were immobilized in supine position on the treat-
ment table, using a commercial stereotactic mask fixation
system in conjunction with the iPlan (BrainLAB, Munich,
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Germany) and Multiplan (Accuray, Sunnyvale, USA)
treatment planning system. Target volumes and organs-at-
risk (OAR) were delineated using postcontrast thin-slice
(1mm) gadolinium-enhanced T1-weighted and
T2-weighted axial MRI sequences fused with thin-slice
(0.75mm) planning computed tomography (CT) scans.
Target delineation and dose prescriptions were based on
international consensus guidelines [8, 14–16]. To better
compare the different treatment regimens, we calculated
the biologically effective dose (BED) for each cavity de-
pending on the number of fractions (Fx) and the single
dose (SD) with a tumor α/β ratio of 10 [17]:
BED ¼ Fx SD 1þ SD=10ð Þ
The following RT parameters were recorded: date of
RT, device used for RT, fractionation, single dose, total
dose, minimum target dose, maximum target dose, mean
target dose, prescription isodose, planning target volume
(PTV), gross tumor volume (GTV), margin and con-
formality index (CI). Radiotherapy outcome measures
included local control (LC), distant brain control (DBC)
and OS.
Follow-up and toxicity assessment
After SRS/HFSRT, all patients were followed at 3-month
intervals with neurological assessment. Serial brain MRI
performance was individually decided by the treating
physician. This was the standard of care in our hospital
during that period of time. All observed adverse events
were graded according to the National Cancer Institute’s
Common Terminology Criteria for Adverse Events,
version 4.0 (CTCAE-NCI v.4.0).
MRI follow-up
Performing the first MRI scan 3 months after RT and/or
performing ≥1 MRI per 180 days was defined as regular
MRI FU. If MRI FU was performed, we have defined
local failure (LF) as the development of new nodular
contrast enhancement in the surgical bed compared with
the baseline postoperative MRI. Local failure for unre-
sected metastases was defined as an increase in size of
more than 25%. Distant brain failure (DBF) was defined
as the development of new, non-contiguous lesions in
either MRI- or CT-follow-up. Leptomeningeal disease
was diagnosed by imaging results consistent with this
condition (either local or diffuse leptomeningeal dis-
ease) and rated as DBF. Diagnoses of tumor progression
or radiation necrosis (RN) were determined based on
histologic findings for patients who underwent surgical
resection or by imaging using magnetic resonance spec-
troscopy (MRS). Lesions that were progressive on imaging
and/or caused new neurological symptoms, but which
dissolved without any further anti-cancer treatment, were
considered RN rather than local failure. Neurological
death was defined as uncontrolled intracranial tumor
progress as well as new or progressive neurological
symptoms prior to death. MRI data measures in-
cluded: performance of a MRI FU 3 months post-RT
(yes vs. no) and number of MRIs per 180 days post-RT
until first salvage treatment. MRI outcome measures
included the correlation between regular MRI FU and
OS, time to any brain failure (ABF, i.e. LF or DBF),
time to salvage treatment, symptom-free survival
(SFS), deferment of WBRT and WBRT-free survival
(WFS).
Statistical analysis
Time to event data was calculated from the day of SRS
or first day of HFSRT to the date of death or censored at
last follow-up using the Kaplan-Meier method. Median
follow-up time was determined with the reverse
Kaplan-Meier method. Concerning OS and DBF, calcula-
tions were on a per patient basis (i.e. patients with more
than one brain lesion were only considered once in the
analysis) and for LF on a per cavity basis. For patients
who had BMs treated sequentially, OS was considered
from the date of the first SRS/HFSRT treatment. Uni-
variate and multivariate Cox regression were used to
investigate factors prognostic for LF, DBF and OS. For
univariate analysis gender, age, primary tumor histology
(breast, non-small cell lung, melanoma, colorectal and
renal cell), residual tumor, GPA score, PTV >15cm3, BED
< 40Gy, MRI FU at 3months and ≥ 1 MRI per 180 days
were evaluated. MRI FU at 3months and all covariates
with a p-value of ≤0.1 in the univariate analysis conce-
rning OS were intended for inclusion in the multivariate
model. Group differences were assessed with the log-rank
test. The association between regular MRI FU and time to
WBRT was calculated with the Mann-Whitney-U-Test. A
p-value ≤0.05 was considered statistically significant. All
statistical analysis was completed using SPSS version 21
(IBM, USA).
Ethics
All patients gave informed consent prior to initiation of
treatment. Research ethics board approval was obtained
for this analysis (Project ID: 2017–00033). This work is




Seventy-five patients were meeting the inclusion cri-
teria of this study, comprising of 43 (57%) women and
Bachmann et al. Radiation Oncology           (2019) 14:45 Page 3 of 14
32 (43%) men. Baseline characteristics are shown in Ta-
bles 1 and 2. A total of 77 resection cavities and 88 BMs
were treated. Most patients (n = 63, 84%) had a single
brain lesion and only 10 (13%) patients had synchronous
BMs. Two (3%) patients received surgery and subsequent
SRS/HFSRT to the surgical cavity for 2 BMs. Median
follow-up time was 32.9 months (95% CI: 28.9–37
months). Median age at the time of RT was 62.9 years
(range 33.3–79.2 years), while 54 (72%) patients had
an ECOG score 0 and 58 (78%) patients had a GPA
score ≥ 2.5. The most frequent primary tumor histolo-
gies were non-small cell lung cancer (n = 37, 49%) and
melanoma (n = 13, 17%). At the time of diagnosis, 70
(93%) patients were symptomatic and total tumor re-
section was achieved in 60 (78%) metastases. A salvage
treatment was administered to 31 (41%) patients. As
first salvage treatment, surgery, SRS and WBRT were
used for 10 (13%), 10 (13) and 11 (15%) patients, re-
spectively. Median time from initial RT to first salvage
treatment or last follow-up/death was 15.7 months
(range, 2.5–30.2 months), while median time from first
salvage treatment to death or last follow-up was 11.2
months (range, 0.3–33.7 months). There was a signifi-
cant difference between groups concerning gender
(p = 0.025), iBMV (p = 0.015) and BMV (p = 0.012)
comparing patients that received ≥1 MRI vs. < 1 MRI
per 180 days. Furthermore, patients that underwent
MRI FU at 3 months had a significantly higher median
iBMV value (p = 0.015).
Treatment characteristics
Dosimetric factors are summarized in Tables 3 and 4.
The most commonly prescribed marginal dose to the
resection cavity was 18 Gy (n = 36, 47%), most often
prescribed to the 80% isodose (median prescription
isodose: 80%, range 70–83%), resulting in a median
mean dose of 18.3 Gy (range 16.6–24.5 Gy) for cavities
treated with SRS. All HFSRTs were prescribed to the
80% isodose and 10 × 4 Gy was most frequently ap-
plied (n = 9, 12%), which resulted in a median mean
dose of 39.9 Gy (range 24–45.7 Gy). Single-fraction
SRS was administered to 60 (78%) cavities, while
HFSRT was used for 17 (22%) cavities delivered in 5, 6
and 10 fractions to 4 (5%), 4 (5%) and 9 (12%) cavities,
respectively. In the SRS-group, median resection cav-
ity volume (GTVres) and median planning target vol-
ume (PTVres) were 4.6 cm
3 (range 0.28–9.6 cm3) and
8.4 cm3 (range 1.8–21 cm3), respectively. In the
HFSRT-group, median GTVres was 15.3 cm
3 (range
2.4–31.3 cm3) and median PTVres 22.6 cm
3 (range
4.9–45.5 cm3). A margin from GTVres to PTVres was
applied to 74 (96%) cavities, while the median margin
was 1.0 mm (range 0–2.5 mm).
Local control and distant brain control
Overall, 77 resection cavities were evaluable on follow-
up MR-imaging. Nine (12%) cavities could not be
assessed for LC, due to death prior to the 3-months
post-RT MRI FU scan (n = 3, 4%), availability of
CT-scans only (n = 2, 3%) or complete loss to imaging
follow-up (n = 4, 5%). While LF was seen in 25 (32%)
resection cavities, DBF occurred in 36 (48%) patients. At
one year, LC and DBC rates were 72% (95% CI: 60–83%)
and 60% (95% CI: 49–72%), respectively (Fig. 1). Median
time to DBF was 16.2 months (95% CI: 4.5–27.9
months), while no median time for LF was reached. No
significant difference in LC and DBC was found for the
different primary tumor histologies, margin and location
of the BMs within the brain.
Overall survival
At last FU, 30 (40%) patients were still alive. Median OS
was 19.4months (95% CI: 13.2–25.6months) with 1- and
2-year OS of 64% (95% CI: 53–75%) and 44% (95% CI:
31–56%), respectively (Fig. 1). While median OS without
any additional in situ BMs was 24.6months (95% CI:
17.2–31.9months), median OS for patients with 1 syn-
chronous BM was 7.1months (95% CI: 6.2–8.1months)
and the one patient with 2 synchronous BMs died 2
months after RT (p < 0.001). Patients with an ECOG score
0 had increased survival (24.6 months, 95% CI: 14.8–34.3
months) compared to patients with an ECOG score 1 (8.8
months, 95% CI: 0–23months) and 2 (10.7months, 95%
CI: 0–23.3months), however, no significance could be
reached (p = 0.131). GPA score significantly correlated
with OS: median survival for GPA 0–2 was 7.6
months (95% CI: 4.2–10.9 months), 20.8 months (95%
CI: 13.8–27.8 months) for GPA 2.5–3 and 36.6 months
(95% CI: 15.1–58.1 months) for GPA 3.5–4 (p = 0.001).
Sixteen patients (21%) died of a neurological death. His-
tology of the primary tumor and receiving any systemic
treatment had no impact on survival (p = 0.379). Similarly,
no beneficial survival difference could be shown for
immunotherapy and/or targeted therapy compared to
cytotoxic chemotherapy (p = 0.186).
Toxicity and radiation necrosis
Post-therapeutic fatigue was the most common ad-
verse event and occurred in 10 (13%) patients. Nine
(12%) patients reported post therapeutic headache
and one patient (1%) suffered from vertigo. Hospitalization
was necessary for 2 (3%) patients due to pneumonia
and impossibility of mobilization, respectively. Rad-
iation necrosis was verified histologically after sur-
gery in 4 (5%) and suspected radiologically in 13
(17%) cavities.
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Table 1 Patient characteristics
Characteristics All patients RT to cavity only RT to cavity and in situ BM p-value
Gender 0.855
Male 32 (43) 26 (35) 6 (8)
Female 43 (57) 39 (52) 4 (5)
Age at diagnosis (years) 62.9 (33.3–79.2) 63.3 (33.3–79.2) 58.2 (42.2–76.1) 0.436
Histology 0.262
Lung 37 (49) 35 (47) 2 (3)
Breast 6 (8) 5 (7) 1 (1)
Melanoma 13 (17) 11 (15) 2 (3)
RCC 2 (3) 2 (3) 0 (0)
Colorectal 8 (11) 6 (8) 2 (3)
Other 9 (12) 6 (8) 3 (4)
Location of cavity 0.441
Supratentorial 61 (79) 54 (70) 7 (9)
Infratentorial 16 (21) 14 (18) 2 (3)
Number of BM < 0.001
1 63 (84) 63 (84) NA
2 11 (15) 2 (3) 9 (12)
3 1 (1) 0 (0) 1 (1)
Fractionation 0.517
SRS 60 (78) 53 (69) 7 (9)
HFSRT 17 (22) 14 (18) 3 (4)
ECOG score 0.305
0 54 (72) 48 (64) 6 (8)
1 14 (19) 12 (16) 2 (3)
2 or NA 7 (9) 5 (6) 2 (3)
GPA score 0.002
3.5–4 23 (31) 23 (31) 0 (0)
2.5–3 35 (47) 32 (43) 3 (4)
0–2 13 (17) 8 (11) 5 (7)
NA 4 (5) 2 (3) 2 (3)
BM symptomatic initially 0.490
No or unknown 5 (7) 4 (5) 1 (1)
Yes 70 (93) 61 (81) 9 (12)
Residual tumor 0.143
No 60 (78) 54 (70) 6 (8)
Yes 17 (22) 13 (17) 4 (5)
Systemic cancer treatment 0.363
No or unknown 37 (49) 32 (43) 5 (7)
Yes 38 (51) 33 (44) 5 (7)
Cytotoxic 25 (33) 22 (29) 3 (4)
Immunotherapy/targeted 6 (8) 4 (5) 2 (3)
Combined 7 (9) 7 (9) 0 (0)
Extracranial tumor status 0.462
Stable 27 (36) 25 (33) 2 (3)
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Factors prognostic for overall survival and intracranial
failure
In multivariate analysis a PTVres > 15 cm
3 (HR 2.29, 95%
CI: 1.22–4.31, p = 0.01), lower GPA score (0–2.0 vs. 2.5–3.0
vs. 3.5–4.0: HR 0.42, 95% CI: 0.26–0.69, p = 0.001) and
residual tumor after surgery (HR 2.4, 95% CI: 1.29–
5.64, p = 0.008) were associated with worse OS. A
PTVres > 15 cm
3 was prognostic for increased LF in
univariate (HR 3.42, 95% CI: 1.54–7.62, p = 0.003) and
multivariate analysis (HR 3.2, 95% CI: 1.37–7.48, p = 0.007).
Also, significantly higher LF rates for cavities which
were irradiated with a BED of < 40 Gy were found in
both uni- and multivariate analysis (HR 5.71, 95% CI:
2.05–15.9, p = 0.001). The two factors prognostic for
DBF in multivariate analysis were PTVres > 15 cm
3 (HR
3.18, 95% CI: 1.34–6.16, p = 0.001) and lower GPA
score (0–2.0 vs. 2.5–3.0 vs. 3.5–4.0: HR 0.46, 95% CI:
0.28–0.74, p = 0.001). The results of the univariate and
multivariate analysis and a summary of outcomes are
shown in Table 5 and 6.
Analyzing group differences with the log-rank test re-
vealed significant shorter time to DBF (8.2 months, 95%
CI: 0–22.1 months, vs. 24.4 months, 95% CI: 11.5–37.3
months, p = 0.009) for patients with synchronous in situ
BMs, as well as patients with progressive extracranial
tumor disease (11.1 months, 95% CI: 6.4–15.7 months
vs. no median reached for patients with stable extracra-
nial tumor disease, p = 0.001). Additionally, patients with
progressive extracranial tumor status had decreased sur-
vival with a median OS of 16.5months (95% CI: 7.1–25.8
months, p = 0.001), while no median OS value was
reached for patients with stable extracranial tumor status.
Patients with a BMV greater than the median had signifi-
cantly reduced OS compared to the group with a BMV
lower than the median (18.5months, 95% CI: 9.9–27.1
months vs. 47.1 months, 95% CI: 21.2–73.1 months,
p < 0.001) as well as reduced SFS (7.5 months, 95% CI:
5.1–10months vs. 15.5months, 95% CI: 8.5–22.5months,
p < 0.001) and reduced WFS (13.4months, 95% CI: 4.5–
22.2months vs. 34.5months, 95% CI: 30.8–52.5months,
p < 0.001). However, OS (p = 0.486), SFS (p = 0.834) and
WFS (p = 0.319) was not decreased for patients with
an iBMV greater than the median. Furthermore,
patients which suffered from new or progressive neuro-
logical symptoms had significantly decreased survival
(p = 0.012): One-year and 2-year survival rates were
57% (95% CI: 42–71%) and 37% (95% CI: 22–52%) for
symptomatic patients and 86% (95% CI: 72–100%)
and 69% (95 CI: 47–90%) for asymptomatic patients.
Impact of regular MRI follow-up
Thirty-eight (51%) patients received ≥1 MRI per 180
days and 40 (53%) patients underwent MRI FU at 3months.
Concerning OS, no significant correlation between
MRI FU at 3 months (p = 0.462) or ≥ 1 MRI per 180
days (p = 0.954) could be seen. Median SFS and median
WFS were 10.2 months (95% CI: 5.7–14.7 months) and
17.7 months (95% CI: 13.2–22.3 months), respectively.
Overall, MRI FU at 3 months had no significant impact
on SFS (p = 0.613), WFS (p = 0.407), deferment of WBRT
(p = 0.955), time to salvage treatment (p = 0.441), time to
ABF (p = 0.492) and survival after salvage treatment
(p = 0.885). Similarly, there was no significant correlation
between ≥1 MRI per 180 days and SFS (p = 0.196), WFS
(p = 0.308), deferment of WBRT (p = 0.268), time to
salvage treatment (p = 0.054), time to ABF (p = 0.175) and
survival after salvage treatment (p = 0.549). Increased OS
was seen in a subgroup analysis of patients with progres-
sive extracranial tumor disease, which had MRI FU at
3 months (18.5 months, 95% CI: 14.7–22.4 months vs.
10.7 months, 95% CI: 6.8–14.7 months, p = 0.162),
although this result did not translate into statistical
significance. Additionally, extracranially progressive
patients with MRI FU at 3 months tended to have
prolonged SFS (10.9 months, 95% CI: 2.7–19.1 months
vs. 6.7 months, 95% CI: 3.7–9.7 months, p = 0.206)
and WFS (17.1 months, 95% CI: 7.6–26.7 months vs.
8.2 months, 95% CI: 4.6–11.8months, p = 0.120),
Table 1 Patient characteristics (Continued)
Characteristics All patients RT to cavity only RT to cavity and in situ BM p-value
Progression 44 (59) 37 (49) 7 (9)
Unknown 4 (5) 3 (4) 1 (1)
Initial BMV 0.55 (0.05–11.4) 0.59 (0.05–11.4) 0.48 (0.13–4.93) 0.705
BMV 0.13 (0–84.4) 0 (0–64.9) 3.97 (1.34–84.4) 0.067
MRI follow-up at 3 months 0.112
No 35 (47) 28 (37) 7 (9)
Yes 40 (53) 37 (49) 3 (4)
No. of MRI per 180 days 1 (0–5.2) 1.1 (0–5.2) 0.3 (0–3.8) 0.083
Values represent numbers (percent) or median (range) if not specified otherwise
RT radiotherapy, BM brain metastasis, RCC renal cell carcinoma, SRS stereotactic radiosurgery, HFSRT hypo-fractionated stereotactic radiotherapy, ECOG Eastern
Cooperative Oncology Group, GPA Graded Prognostic Assessment, NA not applicable, BMV brain metastasis velocity
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Table 2 Patient characteristics regarding MRI follow-up
Characteristics MRI FU at 3 months No MRI FU at 3 months p-value ≥1 MRI per 180 days < 1 MRI per 180 days p-value
Gender 0.662 0.025
Male 22 (29) 21 (28) 17 (23) 26 (35)
Female 18 (24) 14 (19) 21 (28) 11 (15)
Age at diagnosis (years) 60.6 (33.3–77.2) 64.4 (42.2–79.2) 0.137 61.1 (33.3–79.2) 62.9 (42.2–76.1) 0.511
Histology 0.079 0.222
Lung 25 (33) 12 (16) 23 (31) 14 (19)
Breast 2 (3) 4 (5) 3 (4) 3 (4)
Melanoma 4 (5) 9 (12) 5 (7) 8 (11)
RCC 1 (1) 1 (1) 0 (0) 2 (3)
Colorectal 2 (3) 6 (8) 2 (3) 6 (8)
Other 6 (8) 3 (4) 5 (7) 4 (5)
Location of cavity 0.473 0.953
Supratentorial 32 (42) 29 (38) 31 (40) 30 (39)
Infratentorial 10 (13) 6 (8) 8 (10) 8 (10)
Number of BM 0.463 0.333
1 35 (47) 28 (37) 34 (45) 29 (39)
2 5 (7) 6 (8) 4 (5) 7 (9)
3 0 (0) 1 (1) 0 (0) 1 (1)
Fractionation 0.688 0.83
SRS 32 (43) 28 (36) 30 (39) 30 (39)
HFSRT 10 (13) 7 (9) 9 (12) 8 (10)
ECOG score 0.513 0.652
0 30 (40) 24 (32) 26 (35) 28 (37)
1 8 (11) 6 (8) 8 (11) 6 (8)
2 or NA 2 (3) 5 (7) 4 (5) 3 (4)
GPA score 0.139 0.291
3.5–4 12 (16) 11 (15) 10 (13) 13 (17)
2.5–3 22 (29) 13 (17) 21 (28) 14 (19)
0–2 4 (5) 9 (12) 5 (7) 8 (11)
NA 2 (3) 2 (3) 2 (3) 2 (3)
BM symptomatic initially 0.387 0.331
No or unknown 3 (4) 2 (3) 3 (4) 2 (3)
Yes 40 (53) 30 (40) 38 (51) 32 (43)
Residual tumor 0.071 0.376
No 36 (47) 24 (31) 32 (42) 28 (36)
Yes 6 (8) 11 (14) 7 (9) 10 (13)
Systemic cancer treatment 0.573 0.978
No or unknown 21 (28) 16 (21) 19 (25) 18 (24)
Yes 19 (25) 19 (25) 19 (25) 19 (25)
Cytotoxic 14 (19) 11 (15) 12 (16) 13 (17)
Immunotherapy/targeted 3 (4) 3 (4) 3 (4) 3 (4)
Combined 2 (3) 5 (7) 4 (5) 3 (4)
Extracranial tumor status 0.743 0.119
Stable 16 (21) 11 (15) 17 (23) 10 (13)
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compared to patients without MRI FU at 3months (Fig.
2). No impact on OS (p = 0.531), SFS (p = 0.479) or
WFS (p = 0.156) was seen in another subgroup analysis
of patients with an iBMV greater than the median that
underwent MRI FU at 3 months. Similarly, performing
an MRI FU at 3 months for patients with a BMV
greater than the median had no effect on OS (p =
0.415), SFS (p = 0.166) or WFS (p = 0.354). On the
other hand, patients with an iBMV greater than the me-
dian that received ≥1 MRI per 180 days seemed to have
worse SFS (12months, 95% CI: 5.8–18.2months vs. 29.1
months, 95% CI: 8.2–45.2months, p = 0.03), while there
was no association with OS (p = 0.173) or WFS (p =
0.156). Also, for patients with a BMV greater than the me-
dian which underwent ≥1 MRI per 180 days significantly
reduced OS (11.9 months, 95% CI: 5.5–18.3 months vs.
25.7 months. 95% CI: 13.4–38 months, p = 0.032) and
WFS (7.8 months, 95% CI: 3.4–12.3months vs. 24.1
months, 95% CI: 8.7–39.5months, p = 0.03), but no asso-
ciation with SFS (p = 0.126) was seen. In uni- and multi-
variate analysis regarding OS, LF and DBF, no significant
results were seen for MRI FU at 3months or ≥ 1 MRI per
180 days (Table 6).
Discussion
Although adjuvant WBRT leads to increased DBC and
less neurological deaths [7, 18, 19], no survival benefit
could be shown compared to adjuvant SRS to the surgi-
cal cavity. Brown et al. [8] recently showed in a ran-
domized phase III trial improved cognitive outcomes
with postoperative SRS in comparison with WBRT,
without OS differences. However, numerous authors
pointed out the increased risk of DBF when WBRT is
omitted [7, 8, 14, 20–23] and emphasized the need for
close brain MRI FU in such patient cohorts [14, 24].
With this current single-center retrospective study, we
report the impact of regular MRI FU for patients with 1
to 3 BMs treated with surgery followed by SRS or
HFSRT to the surgical cavity. To our knowledge, this is
the first report focussing on the impact of regular MRI
FU in patients with a limited number of brain metas-
tases treated with surgery and focal RT. Our general
study results about oncological outcome are well com-
parable with the existing literature. We report excellent
median OS of 19.4 months (95% CI: 13.2–25.6 months)
in our cohort, compared with 10.9 to 17 months de-
scribed in literature [8, 14, 20, 24]. Actuarial LC and
DBC one year after RT were 72% (95% CI: 60–83%)
and 60% (95% CI: 49–72%), respectively. These rates
coincide with the literature, where reported 1-year LC
is 71 to 90% and 1-year DBC 36 to 53% [14, 20–22, 24].
We were also able to confirm in multivariate analysis,
as described in the literature [20–22, 24–27], that the
following factors were prognostic for significantly worse
survival: a PTV > 15 cm3 (p = 0.01), residual tumor after
resection (p = 0.008) and a lower GPA score (0–2.0 vs.
2.5–3.0 vs. 3.5–4.0, p = 0.001). Likewise, additional in
situ BMs (p < 0.001) and progressive neurological symp-
toms (p = 0.012) were associated with worse survival.
Against our hypothesis, regular MRI FU in such a cohort,
consisting mainly of patients with a single and resected
BM, surprisingly did not result in increased OS, SFS, WFS
or deferment of WBRT. However, patients with extra-
cranial progressive tumor disease which received MRI FU
3months after SRS/HFSRT had increased OS (p = 0.162),
SFS (p = 0.203) and WFS (p = 0.120), compared to pa-
tients without MRI FU at 3 months, although these dif-
ferences between groups did not translate into
statistical significance. Nevertheless, one could
hypothesize, that patients with extracranially progres-
sive disease may profit more from regular MRI FU, be-
cause of the increased metastatic spread efficiency with
an uncontrolled primary tumor status [28]. Likewise,
having more than one BM at diagnosis could be an in-
dication of a further progressed primary tumor. Several
studies stated that apart from systemic progression, a
primary pathology of melanoma and ≥ 3 BMs are prog-
nostic for DBF [14, 21, 29]. While tumor histology (p =
0.535) had no impact on DBF in our cohort in univari-
ate analysis, additional unresected BMs (p = 0.009) and
uncontrolled primary tumor status (p = 0.001) were sig-
nificantly associated with shorter time to DBF. To de-
velop the aforementioned hypothesis further, patients
with more than one BM and/or melanoma tumor hist-
ology might therefore benefit more from regular MRI
FU. In contrast, one might speculate that concerning
OS, SFS and WFS, patients with a single and resected
BM and/or controlled primary tumor status do not
Table 2 Patient characteristics regarding MRI follow-up (Continued)
Characteristics MRI FU at 3 months No MRI FU at 3 months p-value ≥1 MRI per 180 days < 1 MRI per 180 days p-value
Progression 22 (29) 22 (29) 18 (24) 26 (35)
Unknown 2 (3) 2 (3) 3 (4) 1 (1)
Initial BMV 0.72 (0.07–11.4) 0.39 (0.05–4.1) 0.015 0.7 (0.12–10.7) 0.39 (0.05–11.4) 0.015
BMV 0.65 (0–84.4) 0 (0–34.8) 0.139 1.33 (0–84.4) 0 (0–34.8) 0.012
Values represent numbers (percent) or median (range) if not specified otherwise
FU follow-up, BM brain metastasis, RCC renal cell carcinoma, SRS stereotactic radiosurgery, HFSRT hypo-fractionated stereotactic radiotherapy, ECOG Eastern
Cooperative Oncology Group, GPA Graded Prognostic Assessment, NA not applicable, BMV brain metastasis velocity
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Fig. 1 a–c Time from SRS or first day of HFRST to death or last
follow-up (a), local failure (b) and distant brain failure (c)
Fig. 2 a-c Impact of MRI follow-up 3 months after radiotherapy (red
graph) on overall survival (a), symptom-free survival (b) and WBRT-
free survival (c) in a subgroup analysis of patients with extracranial
progressive tumor disease
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profit as much from regular MRI FU, which could be
the reason why we were not able to show a significant
impact of regular MRI FU in our cohort (84% of our
patients had a single and resected BM).
Farris et al. [13] introduced the novel metric BMV,
which is defined as the cumulative number of new BM
that developed over time since first SRS in years. The
authors were able to show that a lower BMV correlated
significantly with increased OS, increased freedom from
WBRT and a reduced incidence of neurological death.
This is of special interest, as BMV might help to decide
if a patient should receive either salvage SRS or WBRT
in case of second DBF. In addition, Soike et al. [12] were
able to show that the metric iBMV (which is defined as
number of BMs at initial SRS devided by time (years)
from initial cancer diagnosis to first SRS) correlated with
BMV and OS. Thus, iBMV could serve as a metric to
help triage patients to initial SRS or WBRT. In our
cohort we can confirm that a BMV greater than the
median is associated with worse OS (p < 0.001), as well
Table 3 Treatment characteristics
Characteristics SRS HFSRT All patients
Days from diagnosis to RT 34 (15–99) 35 (23–61) 34 (15–99)
Device used for RT
Novalis (BrainLAB) 40 (52) 12 (16) 52 (69)
Cyberknife (Accuray) 20 (26) 5 (6) 23 (31)
GTVres 4.6 (0.3–9.6) 15.3 (2.4–31.3) 5.37 (0.3–31.3)
PTVres 8.4 (1.8–21) 22.6 (4.9–45.5) 10.6 (1.8–45.5)
PTVres ≥ 15 6 (8) 14 (18) 20 (26)
PTVres < 15 54 (70) 3 (4) 57 (74)
Cavity min. Dose 17.2 (6.3–19.7) 36.9 (19.3–40) 17.5 (6.3–40)
Cavity mean dose 18.3 (16.6–24.5) 39.9 (24–45.7) 19.2 (16.6–45.7)
Cavity max. Dose 19.1 (17–20.4) 40.4 (24.2–50) 20.4 (17–50)
Isodose line in % 80 (70–83) 80 80 (70–83)
Margin used for cavity
0 3 (4) 0 (0) 3 (4)
0.5–1.5 40 (52) 12 (16) 52 (68)
1.8–2.5 17 (22) 5 (6) 22 (28)
Median margin for cavity 1 (0–2.5) 1 (1–2) 1 (0–2.5)
Conformality index 1.14 (1–1.68) 1.12 (1–1.67) 1.13 (1–1.68)
Patients with in situ BMs 7 (9) 3 (4) 10 (13)
GTVin situ 0.46 (0.19–1.67) 0.85 (0.06–2.18) 0.47 (0.06–2.18)
PTVin situ 0.48 (0.42–1.67) 1.05 (0.38–3.48) 0.51 (0.38–3.48)
Min. dosein situ 19.8 (18.6–21.5) 19.8 (19.6–38.3) 19.9 (18.6–38.3)
Mean dosein situ 22.7 (22–24.1) 21.4 (21.1–43.6) 22.6 (21.1–43.6)
Max. dosein situ 25 (22.5–25.3) 22.2 (21.8–47.5) 25 (21.8–47.5)
Values represent numbers (percent) or median (range) if not specified otherwise. Values for volume, margin and dose are reported in cm3, mm and
Gy, respectively
SRS stereotactic radiosurgery, HFSRT hypo-fractionated stereotactic radiotherapy, RT radiotherapy, GTV gross tumor volume, PTV planning target volume, Res
resection cavity, BMs brain metastases
Table 4 Single and multi-fractions schemes used for the
cavities
Fx SD [Gy] TD [Gy] BED [Gy] Cavities
1 15 15 37.5 4 (5%)
17 17 45.9 12 (16%)
18 18 50.4 36 (47%)
20 20 60 8 (10%)
5 5 25 37.5 1 (1%)
6 30 48 3 (4%)
6 4 24 33.6 2 (3%)
5 30 45 2 (3%)
10 4 40 56 9 (12%)
Fx fractions, SD single dose, TD total dose, BED biologically effective dose
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as worse SFS (p < 0.001) and WFS (p < 0.001). On the
other hand, iBMV had no impact on OS, SFS or WFS.
Median BMV value was 0.13 in our cohort and hence
noticeably lower compared to a median value of 5.5 in
the cohort of Farris et al. [13]. In the study of Soike et
al. [12], the iBMV value differed significantly depending
on the primary tumor. The iBMV tends to be higher for
tumor histologies that spread faster or more likely to the
brain. On that account, we believe that iBMV is a surro-
gate marker for tumor biology and therefore also for
histology. Since tumor histology had no impact on OS in
our cohort, it is well explicable that iBMV was also not
associated with OS. Concerning OS, SFS and WFS no
benefit was seen for patients with an iBMV or BMV
greater than the median, which underwent regular MRI
FU. In fact, patients with an iBMV greater than the me-
dian that received ≥1 MRI per 180 days had significantly
worse SFS (p = 0.03) and patients with a BMV greater
than the median which received ≥1 MRI per 180 days
had significantly reduced OS (p = 0.032) and WFS
(p = 0.03). There seems to be a discrepancy concerning
the benefit of regular MRI FU for patients with an
increased risk of potentially developing new BMs (i.e.
extracranial progressive tumor disease) and for patients
that effectively develop more new BMs (i.e. increased
BMV). It has to be noted that the median iBMV was a
Table 5 Uni- and multivariate analysis regarding local failure, distant brain failure and overall survival
Univariate Multivariate
HR (95% CI) p-value HR (95% CI) p-value
Local failure
Gender 1.26 (0.57–2.77) 0.573
Age 1 (0.97–1.04) 0.912
Histology 1.08 (0.83–1.4) 0.576
Residual tumor 1.22 (0.42–3.58) 0.712 1.55 (0.47–5.1) 0.475
GPA score 0.66 (0.36–1.21) 0.18 0.82 (0.42–1.59) 0.552
PTVres > 15 cm
3 3.42 (1.54–7.62) 0.003 3.2 (1.37–7.48) 0.007
BED < 40 Gy 6.33 (2.5–15.9) < 0.001 5.71 (2.05–15.9) 0.001
MRI FU at 3 months 0.97 (0.43–2.16) 0.936 0.96 (0.39–2.37) 0.926
≥ 1 MRI per 180 days 1.4 (0.63–3.14) 0.412
Distant brain failure
Gender 1.18 (0.62–2.24) 0.61
Age 1.02 (0.99–1.05) 0.201
Histology 1.07 (0.87–1.32) 0.535
Residual tumor 1.26 (0.58–2.73) 0.559 1.52 (0.67–3.45) 0.322
GPA score 0.42 (0.26–0.67) < 0.001 0.46 (0.28–0.74) 0.001
PTVres > 15 cm
3 3.7 (1.97–6.97) < 0.001 3.18 (1.34–6.16) 0.001
BED < 40 Gy 2.1 (0.78–5.68) 0.143 1.31 (0.45–3.8) 0.623
MRI FU at 3 months 0.97 (0.52–1.81) 0.912 1.19 (0.59–2.38) 0.628
≥ 1 MRI per 180 days 1.44 (0.76–2.71) 0.262
Overall survival
Gender 1.57 (0.86–2.88) 0.141
Age 1.01 (0.98–1.04) 0.637
Histology 1.65 (0.96–1.41) 0.115
Residual tumor 2.91 (1.58–5.38) 0.001 2.4 (1.29–5.64) 0.008
GPA score 0.39 (0.24–0.62) < 0.001 0.42 (0.26–0.69) 0.001
PTVres > 15 cm
3 2.67 (1.47–4.85) 0.001 2.29 (1.22–4.31) 0.01
BED < 40 Gy 3.38 (1.31–8.7) 0.012 2.28 (0.82–6.33) 0.113
MRI FU at 3 months 0.8 (0.44–1.45) 0.461 1 (0.52–1.92) 0.993
≥ 1 MRI per 180 days 1.5 (0.83–2.72) 0.183
HR hazard ratio, CI confidence interval, GPA Graded Prognostic Assessment, PTVres planning target volume, BED biologically effective dose, MRI FU magnetic
resonance imaging follow-up
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significantly higher in the patient cohort that underwent
MRI FU at 3months and those that received ≥1 MRI per
180 days (see Table 2, for both p = 0.015). Similarly, a sig-
nificant higher median BMV value was seen for patients
that underwent ≥1 MRI per 180 days (p = 0.012). A reason
for this group differences might be selection bias, as the
performance of regular MRI FU was at the physician’s dis-
cretion. Therefore, in our retrospective study, it is prob-
able that patients with primary tumor histologies that are
known to predominantly metastasize to the brain (i.e. lung
cancer) are more likely to be selected into the “regular
MRI FU group”. Another reason for the imbalance is
probably due to the fact that regular MRI FU shortens the
time to detect new BMs, which results in a higher BMV.
All above mentioned limitations indicate that the results
concerning iBMV/BMV and regular MRI FU have limited
validity in our cohort. Also, the counterintuitive and il-
logical results concerning regular MRI FU and increased
iBMV/BMV indicate that the impact of regular MRI FU
might be of less significance than previously presumed in
a cohort consisting of patients with a good performance
status and with a single and resected BM. Therefore, a
prospective evaluation of the impact of regular MRI FU is
needed.
Nevertheless, to be able to deliver local radical therapies
effectively (initially or as salvage treatment), precise tumor
imaging with brain MRI is paramount [14, 22, 23, 28]. In a
retrospective review of patients receiving salvage SRS after
prior brain RT, Kurtz et al. [30] were able to show that es-
pecially younger patients with controlled extracranial
tumor disease and durable response to initial brain RT
presumably profit the most from salvage SRS. The authors
concluded that this circumstance implies the need for
intracranial monitoring for these patient groups. Ad-
ditionally, preventing new or progressing symptoms
and delivering SRS initially (and thus deferring WBRT
and its neurotoxic effects with an increased risk of
DBF) are other mentioned reasons in literature pro-
posing the need of regular MRI FU [7]. Chang et al.
[23] stated in their randomized trial that the benefit of
close imaging surveillance is supported by the fact that 18
out of 21 patients with DBF were asymptomatic when
recurrences were discovered in MRI FU. Furthermore, it
is crucial to bear in mind that neurocognitive decrease
can result from both WBRT and recurrent brain metasta-
ses. In order to reduce the impact of recurrent metastases
on neurocognition, many authors advocate performing
regular MRI FU, as salvage surgery and SRS can be
repeated [14, 23, 31]. Preventing symptoms caused by
recurring BMs is not only desirable from a clinical point
of view, but possibly also for the health care system. On
average, management of symptomatic patients noticeably
drains more on the resources, as they are more likely to
undergo neurosurgical interventions and tend to have
Table 6 Summary of outcomes
Outcome Definition Result
Overall survival Survival after SRS/HFSRT 19.4 months (95%
CI: 13.2–25.6 months)
Local control Absence of new nodular contrast enhancement in the surgical bed compared
with the baseline postoperative MRI.
1 year rate: 72%
(95% CI: 60–83%)
Distant brain control Absence of new, non-contiguous lesions in either MRI- or CT-follow-up.
Leptomeningeal disease was rated as DBF.
1 year rate: 60%
(95% CI: 49–72%),
Radiation necrosis Determined based on histologic findings (after surgery) or magnetic resonance spectroscopy
(MRS).
17 (22%)
Neurological death Uncontrolled intracranial tumor progress or new/progressive neurological
symptoms prior to death
16 (21%)
Time to any brain
failure
Time after initial SRS/HFSRT to local failure or distant brain failure 13.9 months
(95% CI: 10.7–17.1 months)
Symptom-free survival Survival after initial SRS/HFSRT without new or progressive neurological
symptoms
10.2 months
(95% CI: 5.7–14.7 months)
WBRT-free survival Survival after initial SRS/HFSRT without undergoing WBRT 17.7 months (95%
CI: 13.2–22.3 months)
Deferment of WBRT Postponing of WBRT (through regular MRI FU) MRI FU at 3 months: p =
0.955








Survival after first salvage therapy 11.2 months (range,
0.3–33.7 months)
SRS stereotactic radiosurgery, HFSRT hypo-fractionated stereotactic radiotherapy, MRI magnetic resonance imaging, FU follow-up, CT computed tomography, DBF
distant brain failure, MRS magnetic resonance spectroscopy, WBRT whole brain radiotherapy
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longer hospital stays, whereas asymptomatic patients can
be managed with outpatient SRS more frequently [9]. In a
retrospective study of patients with mostly oligometastatic
brain disease (89% of the patients had ≤3 BMs) who re-
ceived upfront SRS, Lester et al. [9] compared the clinical
and economical outcomes of asymptomatic and symp-
tomatic patients. The authors created a model of 5000
patients who underwent regular MRI FU and evaluated its
possible financial benefit based on the survival rate of
asymptomatic patients, time to DBF, MRI costs, estimated
detection rate of new lesions and estimated costs of
managing symptomatic and asymptomatic metastases.
Based on this model, they estimated that surveillance
brain imaging after radiosurgery could save insurers an
average of $1326 per patient.
Nevertheless, since there are no prospective trials that
analyzed the impact of regular MRI FU, the actual bene-
fit remains unclear. In addition, Yiu et al. [32] stated that
close surveillance imaging might also induce anxiety and
lower the patient’s quality of life. In their feasibility
survey about the benefit of MRI FU, the authors were
able to show that within 6 months 10 (45%) out of 22
patients agreed to participate in the experimental arm
without regular MRI surveillance. A prospective cohort
study would therefore be feasible.
We could not confirm a significant correlation be-
tween OS and ECOG/KPS score in our cohort. A reason
for increased OS in our cohort might be due to stricter
patient selection: Sixty-eight (91%) patients had an
ECOG of 0–1, 63 (84%) had a single BM and 58 (78%) a
GPA score ≥ 2.5. Referring to the recent phase III trial of
Brown et al. [8], the reported median OS was 12.2
months, while 90% had an ECOG 0–1 and 23% of the
patients treated with SRS after surgery had > 1 BMs.
Similarly, Choi et al. [14] reported a median OS of 17
months, while only 63% had a single BM and 24% had a
GPA score > 3.
Therefore, some important limitations should be
acknowledged in our study. Being of retrospective na-
ture, this study is limited by inherent biases. Any conclu-
sions revealed here are hypothesis-generating and, as
such, need to be validated within a prospective study.
There may be a selection bias in our patient cohort, as
only patients with adjuvant SRS were taken into account.
Patients with poorer prognosis and hence poorer perform-
ance score were less likely to receive SRS. A reporting bias
is also probable, as patients in poor general health condi-
tion were less likely to undergo complete follow-up
scheme or were lost to follow-up and therefore excluded
from the study due to lack of data. Regular MRI FU was
often not performed strictly according to the guidelines,
which resulted in a large heterogeneity of different FU in-
tervals. Also, since the performance of regular MRI FU
was at the physician’s discretion, a bias in patient selection
in this regard seems probable. Therefore, a prospective
study assessing the impact of regular MRI FU is needed.
Conclusion
Our results regarding oncological outcomes consist with
the current data from the literature. Overall, regular
MRI FU did not result in increased OS, SFS, WFS or
deferment of WBRT in our cohort consisting mainly of
patients with a single and resected BM. Based on a sub-
group analysis concerning OS, SFS and WFS, we found
that patients with progressive extracranial tumor disease
might profit more from regular MRI FU. The impact of
regular MRI FU needs prospective evaluation.
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